Market Cap 190.24M
Revenue (ttm) 0.00
Net Income (ttm) -46.27M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 458,204
Avg Vol 978,256
Day's Range N/A - N/A
Shares Out 115.65M
Stochastic %K 9%
Beta 1.47
Analysts Strong Sell
Price Target $8.25

Company Profile

NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 745 6330
Address:
2440 Research Boulevard, Suite 400, Rockville, United States
Latest News on NBP
NovaBridge Biosciences Slides: Company presentation

Apr 15, 2026, 7:00 AM EDT - 7 weeks ago

NovaBridge Biosciences Slides: Company presentation


NovaBridge Biosciences Earnings release: Q4 2025

Apr 7, 2026, 7:00 AM EDT - 2 months ago

NovaBridge Biosciences Earnings release: Q4 2025


NovaBridge Biosciences Annual report: Q4 2025

Apr 7, 2026, 7:00 AM EDT - 2 months ago

NovaBridge Biosciences Annual report: Q4 2025


NovaBridge Biosciences Transcript: Status update

Mar 9, 2026, 9:00 AM EDT - 3 months ago

NovaBridge Biosciences Transcript: Status update


NovaBridge Biosciences Press release: Status update

Mar 9, 2026, 9:00 AM EDT - 3 months ago

NovaBridge Biosciences Press release: Status update


NovaBridge Biosciences Slides: Status update

Mar 9, 2026, 9:00 AM EDT - 3 months ago

NovaBridge Biosciences Slides: Status update


NovaBridge Biosciences Slides: Investor presentation

Feb 23, 2026, 6:00 AM EST - 3 months ago

NovaBridge Biosciences Slides: Investor presentation


NovaBridge resumed with a Buy at H.C. Wainwright

2026-02-06T11:12:13.000Z - 4 months ago

NovaBridge resumed with a Buy at H.C. Wainwright


NovaBridge Biosciences Transcript: Investor Update

Oct 16, 2025, 4:45 PM EDT - 8 months ago

NovaBridge Biosciences Transcript: Investor Update


NovaBridge Biosciences Press release: Investor Update

Oct 16, 2025, 4:45 PM EDT - 8 months ago

NovaBridge Biosciences Press release: Investor Update


I-Mab to Participate in September Investor Conferences

Aug 21, 2025, 7:00 AM EDT - 10 months ago

I-Mab to Participate in September Investor Conferences


NovaBridge Biosciences Earnings release: Q2 2025

Aug 20, 2025, 7:00 AM EDT - 10 months ago

NovaBridge Biosciences Earnings release: Q2 2025


Everest Medicines Expands Strategic Investment in I-MAB

Aug 1, 2025, 8:56 AM EDT - 11 months ago

Everest Medicines Expands Strategic Investment in I-MAB


NovaBridge Biosciences Transcript: Status Update

Jul 8, 2025, 2:00 PM EDT - 11 months ago

NovaBridge Biosciences Transcript: Status Update


I-Mab to Present at Jefferies Global Healthcare Conference

May 20, 2025, 7:00 AM EDT - 1 year ago

I-Mab to Present at Jefferies Global Healthcare Conference


NovaBridge Biosciences Earnings release: Q1 2025

May 15, 2025, 7:00 AM EDT - 1 year ago

NovaBridge Biosciences Earnings release: Q1 2025


NovaBridge Biosciences Earnings release: Q4 2024

Apr 3, 2025, 4:00 PM EDT - 1 year ago

NovaBridge Biosciences Earnings release: Q4 2024


NovaBridge Biosciences Annual report: Q4 2024

Apr 3, 2025, 4:00 PM EDT - 1 year ago

NovaBridge Biosciences Annual report: Q4 2024


I-Mab Reports Third Quarter 2024 Results

Nov 14, 2024, 7:00 AM EST - 1 year ago

I-Mab Reports Third Quarter 2024 Results


NovaBridge Biosciences Earnings release: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

NovaBridge Biosciences Earnings release: Q3 2024


NovaBridge Biosciences Slides: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

NovaBridge Biosciences Slides: Q3 2024


I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer

Nov 6, 2024, 7:00 AM EST - 1 year ago

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer


I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

Sep 16, 2024, 4:01 PM EDT - 1 year ago

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024


NovaBridge Biosciences Earnings Call Transcript: H1 2024

Aug 28, 2024, 8:00 AM EDT - 1 year ago

NovaBridge Biosciences Earnings Call Transcript: H1 2024


NovaBridge Biosciences Quarterly report: H1 2024

Aug 28, 2024, 8:00 AM EDT - 1 year ago

NovaBridge Biosciences Quarterly report: H1 2024


NovaBridge Biosciences Slides: Corporate Presentation

Aug 28, 2024, 7:00 AM EDT - 1 year ago

NovaBridge Biosciences Slides: Corporate Presentation


I-Mab to Release 1H 2024 Financial Results on August 28, 2024

Aug 14, 2024, 7:00 AM EDT - 1 year ago

I-Mab to Release 1H 2024 Financial Results on August 28, 2024


I-Mab Announces Leadership Transitions

Jul 15, 2024, 7:30 AM EDT - 2 years ago

I-Mab Announces Leadership Transitions